WO2008121355A1 - Traitement des symptômes de dermatose touchant un tégument mammalien avec des formulations désinfectantes émollientes - Google Patents
Traitement des symptômes de dermatose touchant un tégument mammalien avec des formulations désinfectantes émollientes Download PDFInfo
- Publication number
- WO2008121355A1 WO2008121355A1 PCT/US2008/004120 US2008004120W WO2008121355A1 WO 2008121355 A1 WO2008121355 A1 WO 2008121355A1 US 2008004120 W US2008004120 W US 2008004120W WO 2008121355 A1 WO2008121355 A1 WO 2008121355A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- jojoba
- composition
- oil
- emollient
- alcohol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 131
- 239000003974 emollient agent Substances 0.000 title claims abstract description 89
- 208000024891 symptom Diseases 0.000 title claims abstract description 15
- 230000003481 dermatitic effect Effects 0.000 title claims abstract description 11
- 239000000645 desinfectant Substances 0.000 title claims description 11
- 238000009472 formulation Methods 0.000 title abstract description 19
- 239000004599 antimicrobial Substances 0.000 claims abstract description 26
- 230000000699 topical effect Effects 0.000 claims abstract description 24
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 23
- 150000002632 lipids Chemical class 0.000 claims abstract description 17
- 210000002374 sebum Anatomy 0.000 claims abstract description 12
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 10
- 241000221095 Simmondsia Species 0.000 claims description 72
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 67
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- 210000003491 skin Anatomy 0.000 claims description 62
- 238000011012 sanitization Methods 0.000 claims description 55
- 229940119170 jojoba wax Drugs 0.000 claims description 53
- 230000036572 transepidermal water loss Effects 0.000 claims description 44
- 150000002148 esters Chemical class 0.000 claims description 42
- 239000000047 product Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- 230000009467 reduction Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 239000003205 fragrance Substances 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 230000003020 moisturizing effect Effects 0.000 claims description 12
- 239000000344 soap Substances 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 11
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 8
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 8
- 206010015150 Erythema Diseases 0.000 claims description 8
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 8
- 229940036350 bisabolol Drugs 0.000 claims description 8
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 8
- 229940042585 tocopherol acetate Drugs 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 239000000049 pigment Substances 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 5
- 206010048222 Xerosis Diseases 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 231100000321 erythema Toxicity 0.000 claims description 5
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 206010024438 Lichenification Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 claims description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 3
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000003899 bactericide agent Substances 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 claims description 3
- 229960000411 camphor oil Drugs 0.000 claims description 3
- 239000010624 camphor oil Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 3
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 3
- 229960005233 cineole Drugs 0.000 claims description 3
- 235000000484 citronellol Nutrition 0.000 claims description 3
- 239000010634 clove oil Substances 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 229940093504 ethyl macadamiate Drugs 0.000 claims description 3
- 235000015203 fruit juice Nutrition 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 239000008169 grapeseed oil Substances 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 239000008633 juniper tar Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 239000006179 pH buffering agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- -1 pro-vitamin Chemical class 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000010677 tea tree oil Substances 0.000 claims description 3
- 229940111630 tea tree oil Drugs 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000011928 denatured alcohol Substances 0.000 claims 2
- 239000000413 hydrolysate Substances 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 230000003292 diminished effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 description 34
- 230000008901 benefit Effects 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- 150000004665 fatty acids Chemical class 0.000 description 15
- 239000004164 Wax ester Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 235000019386 wax ester Nutrition 0.000 description 11
- 238000007127 saponification reaction Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 150000002191 fatty alcohols Chemical class 0.000 description 7
- 210000004247 hand Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000004909 Moisturizer Substances 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001333 moisturizer Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 235000019493 Macadamia oil Nutrition 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000010469 macadamia oil Substances 0.000 description 4
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 4
- 238000007388 punch biopsy Methods 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 210000000707 wrist Anatomy 0.000 description 4
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 3
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 3
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000005250 alkyl acrylate group Chemical group 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 244000028821 Annona squamosa Species 0.000 description 2
- 235000005274 Annona squamosa Nutrition 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010058898 Hand dermatitis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 244000044822 Simmondsia californica Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000010511 apple seed oil Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 150000002194 fatty esters Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000001875 irritant dermatitis Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 229920000223 polyglycerol Chemical class 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical class CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000002272 Annona cherimola Nutrition 0.000 description 1
- 235000005288 Annona lutescens Nutrition 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001644894 Khaya senegalensis Species 0.000 description 1
- 240000007575 Macadamia integrifolia Species 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 238000013474 audit trail Methods 0.000 description 1
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KIZFHUJKFSNWKO-UHFFFAOYSA-M calcium monohydroxide Chemical compound [Ca]O KIZFHUJKFSNWKO-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- UNYOJUYSNFGNDV-UHFFFAOYSA-M magnesium monohydroxide Chemical compound [Mg]O UNYOJUYSNFGNDV-UHFFFAOYSA-M 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 229940078555 myristyl propionate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001300 quillaia extract Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010801 sewage sludge Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- KANINNSSRWMGIP-UHFFFAOYSA-M sodium;butyl 4-hydroxybenzoate;dodecyl sulfate;hexadecan-1-ol;methyl 4-hydroxybenzoate;octadecan-1-ol;propane-1,2-diol;propyl 4-hydroxybenzoate Chemical compound [Na+].CC(O)CO.COC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1.CCCCOC(=O)C1=CC=C(O)C=C1.CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCO KANINNSSRWMGIP-UHFFFAOYSA-M 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- YRZGMTHQPGNLEK-UHFFFAOYSA-N tetradecyl propionate Chemical compound CCCCCCCCCCCCCCOC(=O)CC YRZGMTHQPGNLEK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
Definitions
- the present invention generally relates to emollient and sanitation compositions; and more particularly, representative embodiments of the present invention generally concern delivery of emollients in topically applied disinfectant formulations.
- Antibiotic resistant strains of disease-causing bacteria such as Staphylococcus aureus
- Staphylococcus aureus are now commonly acquired in hospital settings due to close contact of patients who are more susceptible to infection and the extensive use of antibiotics, which generally provide selection pressure for these strains of bacteria. Consequently, people infected with these microbes are likely to have longer hospital stays and may require treatment with second- and third- choice antibiotics that may be less effective and more expensive.
- non-compliance with these policies has been reported to be between 45% and 70%.
- a prominent reason cited for non-compliance is the incidence of acute and chronic irritated skin and, to a lesser extent, contact allergic hand dermatitis due to repeated use of antibacterial soaps and the use of alcohol-based (either ethanol or isopropanol, 60%- 95% wt/wt) hand sanitizers.
- the use of these sanitizers can be as high as fifty or more times during each work day.
- the chronic stripping of the lipid barrier usually results in xerosis, scaling, erythema, rough skin, and tight skin.
- More serious and painful side effects include inflammation, fissures, allergic contact dermatitis, and the harboring of transient pathogenic organisms that may cause infections.
- Common sensations associated with de-lipidization include itching, tingling, burning, stinging, and the like.
- the present invention provides compositions and methods for providing botanically-sourced and/or botanically-derived topical emollient compositions with disinfectant properties to ameliorate dermatitic symptoms of mammalian integument.
- the sanitizing component of the composition may include an antimicrobial sanitizer.
- the emollient component of the composition may include botanical lipid materials (and/or their derivatives) selected to demonstrate properties at least partially analogous to mammalian sebum.
- the combination of sanitizing and emollient components of the resulting formulations may be employed to manage dermatitic symptoms and sanitize mammalian integument.
- FIG. 1 illustrates clinical data relating to transepidermal water loss (TEWL) associated with use and non-use of an emollient sanitizing formulation in accordance with a representative embodiment of the present invention
- FIG. 2 illustrates clinical data relating to TEWL associated with use and non-use of an emollient sanitizing formulation in accordance with a representative embodiment of the present invention
- FIG. 3 is a photomicrographic representation of a cross-section of human skin tissue obtained via punch biopsy prior to application of an emollient sanitizing composition in accordance with a representative embodiment of the present invention
- FIG. 4 is a photomicrographic representation of a cross-section of human skin tissue obtained via punch biopsy after fourteen (14) days of regular application (at least 8 times/day) of an emollient sanitizing composition in accordance with a representative embodiment of the present invention.
- Various representative implementations of the present invention may be applied to any system for providing botanically-sourced (or botanically-derived) topical emollient sanitizing compositions.
- the terms “derivative,” “extract,” “source,” or any combinatorial, variational or contextual equivalent thereof are generally intended to include anything that may be regarded as at least being susceptible to characterization as, or generally referring to, one or more compounds as they exist in nature and/or chemically altered forms thereof.
- the terms “sanitize”, “sanitizing”, “sanitization”, or any combinatorial, variational or contextual equivalent thereof, are generally intended to include anything that may be regarded as at least being susceptible to characterization as, or generally referring to, a material having anti-microbial, bactericidal, antiviral and/or disinfectant activity, including the prevention and/or inhibition of growth and/or killing of bacteria, viruses, fungi of any kind and by any mechanism of action or system of activation.
- topical formulation As used herein, the terms “topical formulation”, “topical composition”, or any combinatorial, variational or contextual equivalent thereof, are generally intended to include anything that may be regarded as at least being susceptible to characterization as, or generally referring to, a cosmetic, a pharmaceutical, a topical medicament, a personal care product, a shampoo, a conditioner, a leave-in conditioner, a hair product, a hair- styling product, a mousse, a nail product, a skin product, a moisturizer, a soap, a body wash, a shaving product, a gel, a lotion, a cream, an ointment, a fragrance, a foundation, a mascara, a gloss, a Hp balm, a lip stick, a lip liner, an eye liner, a cosmetic remover, a cleanser, a scrub, a wax, a spray, a foam, a paste, a solid, a liquid, a towelette, a napkin, a feminine hygiene product,
- topical application or any combinatorial, variational or contextual equivalent thereof, is generally intended to include anything that may be regarded as at least susceptible to characterization as, or generally referring to, use of a topical composition or topical formulation on or in conjunction with the hair, skin or a component layer of the skin, nails and/or any surface of any subject (animate or otherwise) or object.
- the terms "subject”, “user”, or any combinatorial, variational or contextual equivalent thereof, are generally intended to include anything that may be regarded as at least being susceptible to characterization as, or generally referring to, an animal, a human, and/or any at least partially porous surface (living or inanimate) suitably adapted for receiving a topical application of a topical formulation or topical composition.
- the term "botanical”, including any combinatorial, variational or contextual equivalent thereof, generally refers to anything that may be regarded as at least being susceptible to characterization as, or generally indicative of, a material or combination of materials that may be sourced, liberated or derived (chemically or otherwise) from a naturally occurring resource.
- botanical and equivalents thereof may certainly be intended to reference the vernacular meaning ordinarily ascribed to the term as designating properties of or relating to plant life, the scope of the term “botanical” (as used herein) should be understood to extend to various other "naturally occurring" materials that may be sourced or otherwise liberated from any material that at one time comprised living matter (plant-based or otherwise; e.g., petrolatum, mineral oil, etc.) and/or other mineral resources.
- living matter plant-based or otherwise; e.g., petrolatum, mineral oil, etc.
- organic As used herein, the terms "organic”, “organic certification”, “organically derived” or any combinatorial, variational or contextual equivalent thereof, are generally intended to include anything that may be regarded as at least being susceptible to characterization as, or generally referring to, materials that have satisfied the criteria of a certification process generally imposed on producers of organic agricultural products. In general, any business supplying natural- and/or naturally-derived products may be certified, including seed suppliers, farmers, food processors, retailers and restaurants.
- Requirements vary from country to country, and generally involve production standards for growing, storage, processing, packaging and shipping that include, for example: (i) avoidance of most synthetic chemical inputs (e.g., fertilizer, pesticides, antibiotics, food additives, etc.), genetically modified organisms, irradiation, and the use of sewage sludge; use of farmland that has been free from chemicals for a number of years (e.g., often, three (3) or more); keeping detailed written production and sales records (e.g., audit trail); maintaining strict physical separation of organic products from non-certified products; submitting to periodic on-site inspections; and other procedures/requirements prescribed by various organic certifying authorities.
- synthetic chemical inputs e.g., fertilizer, pesticides, antibiotics, food additives, etc.
- genetically modified organisms e.g., irradiation, and the use of sewage sludge
- farmland that has been free from chemicals for a number of years (e.g.,
- the terms “improvement”, “improved”, “benefit”, “beneficial”, or any combinatorial, variational or contextual equivalent thereof may mean an increased incidence in observance of a favorable property or a decreased incidence in observance of an unfavorable property. That notwithstanding, these same terms may also refer to a decrease in incidence in observance of what may correspond in alternative, conjunctive or sequential applications to an otherwise favorable property or the increase in incidence in observance of an otherwise unfavorable property.
- a detailed description of a representative embodiment namely a composition and method for providing a botanically-sourced or botanically-derived topical emollient sanitizing composition, is provided as a specific enabling disclosure that may be generalized to any application of the disclosed compositions and methods in accordance with various representative aspects of the present invention.
- the present invention relates to botanically-sourced and botanically-derived topical emollient compositions having disinfectant properties.
- a composition may comprise a sanitizing component and a botanically-sourced or botanically-derived emollient component.
- a suitable emollient sanitizing composition may comprise an anti-microbial sanitizer and a botanically- sourced or botanically-derived emollient.
- the emollient sanitizing composition may representatively be applied to a topical surface of a subject, such as the skin of a mammalian subject.
- the emollient sanitizing composition may then be rubbed on the skin until the emollient components are substantially absorbed and/or the sanitizing components are substantially evaporated or otherwise dissipated.
- the disclosed emollient sanitizing compositions may be implemented to at least maintain or otherwise improve lipid profiles of the skin of a mammalian subject while concurrently, conjunctively or sequentially sanitizing the skin's surface after application.
- an anti-microbial sanitizer may comprise any composition suitably adapted to provide an at least partially disinfecting function when topically applied to a surface.
- a suitable anti-microbial sanitizer may at least partially penetrate cell walls of bacteria and denature proteins within the cells. This denaturing generally operates to interrupt the life -cycle of the bacterium, thereby killing it.
- representative sanitizing compositions may include alcohols and/or other disinfectant/anti-microbial formulations and/or botanical extracts (or derivatives thereof) including, but not limited to, chlorhexidine gluconate, benzalkonium chloride, iodine, grapeseed oil, lemon juice, tea tree oil, citronellol, camphor oil, cade oil, eucalyptol, clove oil, and/or the like.
- an anti-microbial sanitizer may comprise a lower hydrocarbon chain alcohol, such as a Ci -4 alcohol.
- the alcohol may comprise ethanol, 2-propanol, and/or n-propanol.
- an anti-microbial sanitizer may further comprise a dermatological active agent, a pharmaceutical composition, an antibiotic, a bactericidal agent, an antiseptic agent, a disinfectant agent, an antiviral agent, a nitrogenous cationic surface-active agent, a fruit juice, a fruit extract, and/or the like.
- a suitable anti-microbial sanitizer may comprise a combination of water and alcohol, such as an ethanol azeotrope.
- alcohol such as an ethanol azeotrope.
- ethanol may be present in concentrations between about 60%-95% (wt/wt).
- an anti-microbial sanitizer may be suitably adapted for combination with a botanically-sourced or botanically-derived emollient composition to provide both sanitizing and moisturizing function.
- a representative emollient composition in accordance with various aspects of the present invention may comprise any components that are suitably adapted for providing moisture retention, reduction of transepidermal water loss (TEWL), smooth feel, softness, increased substantivity, and/or the like. Additionally, representative emollient compositions may be employed to soften or smooth the skin by reducing roughness, cracking, irritation, and/or the like.
- a botanically -source or botanically-derived emollient may be selected to provide a lipid profile substantially similar to that of mammalian sebum (e.g., human sebum).
- botanical emollient compositions may include bland, fatty, oleaginous substances that smooth the skin by penetration into the surface layers of skin tissue through the action of rubbing and massaging after application by the user.
- Sources of representative botanical emollients in accordance with various aspects of the present invention include a number of fatty acids, wax esters, sterols, and/or the like (e.g., jojoba oil, shea oil, macadamia oil, rice bran wax, African dry zone mahogany seed oil, custard apple seed oil, sugar apple seed oil, common seabuckthorn seed oil, and/or the like - including derivatives thereof).
- Fatty acids generally comprise aliphatic hydrocarbons or other organic chains with carboxylic substitutes therein, typically having between 8 and 24 carbon atoms in the backbone.
- Fatty acids generally include at least one of stearic acid, oleic acid, myristic acid and palmitic acid.
- Typical fatty acids include linoleic acid, behenic acid, arachidic, lignoceric, and other common fatty acids of the general formulae C n Hp n+1) COOH, C n Hp n-1) COOH or C n Hp n-3) COOH where "n" is an integer from 8 to 24.
- Fatty alcohols have been found to be less sticky and less heavy than many other fatty materials (such as fatty acids), and are frequently used to improve the viscosity and stability of lotions and creams.
- Representative examples of fatty alcohols which find use in cosmetics and personal care products are cetyl alcohol, lauryl alcohol, stearyl alcohol, and oleyl alcohol.
- emollients include fatty esters.
- One of the qualities of fatty esters is that they generally do not feel as oily to the touch as some other types of fatty emollient ingredients.
- Representative examples include isopropyl palmitate, isopropyl myristate, myristyl propionate, ethylhexyl palmitate, and glyceryl stearate.
- a topical emollient composition may be derived or extracted from a botanical source.
- a botanically-sourced (or botanically-derived) emollient composition may include fatty acids, esters of fatty acids, alkoxylated fatty acids, fatty alcohols, esters of fatty alcohols, esters of fatty alcohols with fatty acids, sugar alcohols, isopropyl esters, wax esters and/or combinations thereof derived from the seed oil of the jojoba plant (Simmondsia chinensis), such as, for example: raw and/or refined jojoba oil, a jojoba ester, hydrogenated jojoba oil, a jojoba hydrolysate, a hydrolyzed jojoba ester, a jojoba alcohol, an alkoxylated jojoba wax, an alkoxylated and at least partially hydrogenated jojoba wax, an al
- a botanical emollient composition may include jojoba oil and/or derivatives including hydrogenated jojoba oil, isopropyl jojobate, jojoba alcohol, jojoba esters, and/or hydrolyzed jojoba esters.
- Jojoba oil and jojoba derivatives according to the present invention may comprise about more than 6% unsaponifiables.
- the term "unsaponifiable” generally refers to a portion of the fat and/or oil (or in the case of jojoba, a wax ester) that is not susceptible to saponification.
- unsaponifiable materials typically comprise components that are naturally found in the fats and/or oils, such as phenols, tocopherols, triterpenes, steroids, sterols, hydrocarbons such as squalene, alcohols, and/or the like.
- Unsaponifiable material may be retained with the saponified material through an in situ saponification process, in which the unsaponifiable material is generally not removed and/or separated from the saponified material.
- a saponification reaction may be accomplished by the hydrolysis of an ester under basic conditions, such as in the presence aqueous alkali metal hydroxides (e.g. , NaOH, LiOH, KOH, CaOH, MgOH, and/or the like) to form an alcohol and a salt of a carboxylic acid.
- aqueous alkali metal hydroxides e.g. , NaOH, LiOH, KOH, CaOH, MgOH, and/or the like
- in situ saponification may be affected through a base -catalyzed hydrolysis reaction between jojoba oil (a liquid wax ester at room temperature) and/or jojoba derivatives and an alkyl alcohol.
- the products of the in situ saponification of jojoba oil typically comprise jojoba hydrolysates, which include a mixture of: (i) salts of jojoba fatty acids (saponifiables); and (ii) non-polar, lipophilic materials (unsaponifiables), with the possibility of other materials also present, depending on the source, state and form of the initial reactant (include residual jojoba wax ester).
- the in situ production of unsaponifiable materials in tandem with saponified material from fats, oils and/or their derivatives having high levels of unsaponifiables in accordance with various aspects of the present invention may provide various benefits in compositions prepared for topical application to the skin of a subject. These benefits may include, for example, moisturization, a desirable texture, substantivity, resistance to wear, and water- and/or rinse-resistance. The presence of high unsaponifiables may also provide occlusive properties to the topical formulation where water is maintained in the skin, providing retained softness and smoothness.
- botanical emollient material comprising in situ products of saponification may function to preserve superior skin feel and substantivity generally attributed to the polar hydrophilic properties of, for example, jojoba oil components.
- emollient materials in accordance with various representative embodiments of the present invention may generally form stable emulsions more readily than those incorporating naturally occurring jojoba oil.
- representative emollient materials may also impart an improved lipid profile to the skin of a subject after multiple treatments, as compared with conventional skin sanitizers.
- botanical emollient components of the disclosed compositions may be employed to at least partially reconstitute the lipid profile of the stratum corneum barrier of the skin by providing lipids and derivatives thereof that chemically resemble human sebum.
- botanical emollient compositions in accordance with the present invention generally provide superior smoothness and substantive skin-feel by being absorbing into the skin and/or maintaining a persisting presence on the surface of the skin.
- Representative botanical emollient and anti-microbial sanitizer compositions may be formulated in any suitable manner.
- a suitably adapted anti-microbial sanitizer may comprise a substantially transparent, translucent and/or opaque liquid.
- a suitably adapted botanical ('sourced' or 'derived') emollient component of the composition may comprise carrier particles, such as natural and/or synthetic emollient beads.
- Representative carrier particles may comprise any suitable synthetic and/or natural components.
- carrier particles at least partially comprising natural emollient beads may be produced from combinations of fatty alcohols, isopropyl esters, wax esters, and/or the like, obtained from jojoba oil and/or jojoba derivatives.
- Carrier particles comprising at least partially synthetic beads may also include components such as polyethylene, petrolatum, ethylhexyl palmitate, and/or the like.
- representative carrier particles may include any suitable texture, size, shape, and/or the like.
- suitably adapted carrier particles may comprise visible mono-sized beads having a diameter on the order of at least about 50 microns to more than about 5,000 microns.
- suitably configured carrier particles may comprise beads that are generally soft and adapted to rub into the skin while leaving substantially no debris behind.
- suitably configured carrier particles may be adapted to carry active ingredients.
- carrier particle beads may be comprised of materials that are solid at room temperature and configured in various shapes and/or sizes.
- carrier particle beads may provide color and/or texture so as to be visible in product suspension.
- the color and/or texture of carrier particles may at least partially assist the user in topical application or delivery of a botanical component of an emollient sanitizing composition to a surface via visual verification of deposition.
- Botanical emollient sanitizing compositions for topical use may be formulated in any suitable manner.
- an anti-microbial sanitizer and a botanical emollient may be combined with one or more additives.
- Representative additives may include, for example: a coloring agent, a dye, a color shifting pigment, a preservative, a pH adjusting material, a pH buffering agent, a thickening agent/polymer, a fragrance material, a polar extract of a fragrance material, water, a polyacrylic acid, polymer, a sugar alcohol, glitter, a special effect pigment, a vitamin, a provitamin, an amino acid, a protein, a peptide, a peptide complex, an active agent, and/or the like.
- a botanical emollient sanitizing composition may be formulated with glycerine (alternatively spelled "glycerin ", but equivalent to glycerine in material respect).
- glycerine generally functions to enhance or at least substantially maintain substantivity of an emollient composition.
- a humectant is generally regarded as a hygroscopic substance and is often a molecule with several hydrophilic groups, most often hydroxyl groups; however, amines and carboxyl groups (sometimes esterified) may be employed as well. Humectants typically demonstrate an affinity to form hydrogen bonds with molecules of water.
- Humectants are often found in many cosmetic products where moisturization is desired, including, for example, moisturizing treatments for the hair.
- Representative examples of humectants include glycerine, propylene glycol (E 1520), butylene glycol, poly glycerol, polyglycerol esters, and glyceryl triacetate (E1518) and the like.
- Others may include polyols like sorbitol (E420), xylitol and maltitol (E965), or polymeric polyols like polydextrose (E1200) or natural extracts like quillaia (E999), or lactic acid or urea, and the like.
- the property of a material demonstrating "substantivity" may generally be regarded as its propensity to persist and reside on a surface to which it is applied. With enhanced substantivity, the combination of glycerine with an emollient may provide improved moisture retention properties.
- a botanical emollient sanitizing composition may be formulated into one or more commercial formulations, as generally illustrated by the Examples given below. The percentages detailed below should be regarded as approximate.
- a representative antibacterial emollient sanitizing composition may be formulated as a hand sanitizer gel in accordance with the following:
- Jojoba OU PEG- 150 Esters 0.10 f Floratech” ⁇ , Chandler, AZ, USA) PEG- 150 Hydrogenated Jojoba
- CARBOPOL Librizol Advanced Materials, Inc., Acrylates/C 10-30 Alkyl Acrylate Cleveland, Ohio, USA
- ETD Crosspolymer 2020 (1.0% in water);
- FLORAMAC 10 and Dermolene are excluded while additional FLORAESTERS K-IOO may be used to modify pH. Fragrance and preservative may also be added.
- Jojoba Esters (and) lsopropyl Jojobate
- Example 3 In this representative formulation, the amount of CARBOPOL, glycerine, FLORAESTERS IPJ, SIMULGEL 600, FLORASOMES, TEA and preservative is reduced as compared to Example 2, while water is added to compensate for the decreased formulation volume. Optionally, fragrance may be excluded as well. [0059] Example 3
- Jojoba Esters (and) lsopropyl Jojobate
- Example 3 illustrates a representative embodiment that may serve to reduce stickiness and/or "tack" otherwise associated with conventional hand sanitizers.
- Example 3 may also reduce production costs.
- representative botanical emollients may comprise
- FLORAESTERS IPJ are generally obtained from the product of incomplete saponification of jojoba oil (Simmondsia chinensis) yielding in approximately equal amounts: wax esters, jojoba alcohols, and isopropyl esters of jojoba fatty acids.
- FLORAMAC 10 corresponds to ethyl esters of macadamia oil ⁇ Macadamia integrifolia) fatty acids. Macadamia oil and FLORAMAC 10 are high in palmitoleic acid (C16:l) - a fatty acid know to be present as a significant fraction of human sebum.
- FLORAESTERS KlOO corresponds to saponification products of jojoba oil in conjunction with unsaponifiable material produced from that reaction.
- FLORAESTERS KlOO is generally comprised of potassium salts of jojoba fatty acids, the corresponding jojoba free fatty alcohols, and a small amount of residual jojoba wax ester.
- FLORASOMES generally comprise jojoba oil randomized with fully hydrogenated jojoba oil, yielding wax esters of varying degrees of unsaturation. Unsaturated alcohols of human sebum have not been fully characterized previously, however, somewhat similar alcohols have been observed in the seed oil of Simmondsia chinsensis.
- FLORAESTERS KlOO provides a significant source of unsaturated alcohols derived from botanically-sourced jojoba oil. Human sebum also contains wax esters, with more active sebaceous glands producing sebum lipids with a higher proportion of C16:l straight chain fatty acids. Similar wax esters may be obtained from, for example, FLORAESTERS IPJ and FLORASOMES - both representing derived compounds from botanically-sourced jojoba oil. Additionally, a C16:l lipid profile similar to that of mammalian sebum may be obtained with FLORAMAC 10 - a derived material of botanically-sourced macadamia oil.
- Disclosed botanical topical emollient sanitizing compositions may be formulated for delivery via in any suitable manner, such as with a towelette, a pre-saturated towelette, a wipe, a napkin, a feminine hygiene product, a spray, a liquid, a gel, a cream, a lotion, a foam, a paste, a facial mask, a soap, and/or any other suitable formulation vehicle.
- representative topical emollient sanitizing compositions may be formulated in a towelette, where the towelette may be suitably adapted to absorb and/or retain the emollient sanitizing composition. Additionally, a towelette may be implemented so as to prevent drying or evaporation of an emollient sanitizing composition.
- the material of the towelette may also be disposable, washable, reusable, and/or the like.
- a topical emollient sanitizing composition may be added to the material of a towelette in sufficient quantity to dampen the towelette material so that the composition may be transferred to the skin or other surface of application upon contact with the towelette.
- the user may rub and/or wipe the towelette on the skin until emollient sanitizing composition is substantially absorbed. Debris on the surface of the skin may be further removed by contact of the towelette material on the skin.
- an emollient sanitizing composition may be formulated to produce a sanitizing and moisturizing detergent for use as, for example, an anti-microbial soap for the removal of apolar bacteria, dirt, grease, oils, and/or the like from skin.
- Apolar materials may be lifted from the skin by association with micelles formed with soap molecules for subsequent washing away with water.
- an emollient sanitizing soap may comprise the products of the saponification of a variety of botanical and/or synthetic fats.
- an emollient sanitizing soap may be provided as a solid, liquid, foam, spray, gel, cream, lotion, and/or the like.
- Representative botanical emollient sanitizing compositions in accordance with the present invention may also be formulated with a skin toner.
- Skin toners generally function to sanitize the skin and diminish the size of pores.
- Conventional skin toners may vary according to their concentration of alcohol.
- an astringent is a type of skin toner that generally comprises alcohol up to about 60%.
- a Skin tonic is a type of skin toner that generally comprises less alcohol than astringents and may have up to about 20% alcohol.
- a skin refresher is a type of skin toner that generally comprises the least amount of alcohol - on the order of about less than 10% alcohol.
- botanical emollient sanitizing compositions may increase the range of applications for skin sanitizing compositions that may be suitably formulated for use by persons in which conventional sanitizing formulations may be contra-indicated.
- individuals with sensitive skin, eczema, shingles, the skin of infants or young children, and/or the like may experience significant adverse dermatitic symptoms upon repeated use of conventional sanitizer products.
- Individuals with these same dermatological conditions generally do not experience such symptoms, or at least observe a reduction of symptoms, after use of botanical emollient sanitizing compositions in accordance with representative embodiments of the present invention.
- botanical emollient sanitizing compositions in accordance with the present invention may also be suitably adapted for use on artificial (e.g., inanimate) surfaces that require sanitization without drying effects.
- an emollient sanitizing composition may be employed to alleviate dermatitis, such as acquired occupational hand dermatitis, and/or the like.
- dermatitis such as acquired occupational hand dermatitis, and/or the like.
- all fourteen (14) participants in the study exhibited substantial reduction of dermatitic symptoms after topical application of the emollient sanitizing composition corresponding to Example 1.
- the study participants used the emollient sanitizing composition a minimum of eight (8) times per day over a fourteen (14) day period.
- the subjects cleansed their hands with CETAPHIL (Galderma Laboratories, L.P., Cham Switzerland) soap, which was used to replace their daily hand soap to provide a baseline reference.
- CETAPHIL Cosmetic Acids, Inc.
- the use of other hand moisturizers and topical products were not permitted during the duration of the study.
- a physician's assessment was conducted to evaluate abnormal skin symptoms.
- TEWL evaporative skin moisture loss
- Table 1 representatively illustrates a physician's clinical assessments of the hands of study participants.
- the physician evaluated both dorsal and palmar sides of the hands before treatment and after fourteen (14) days of treatment.
- Subjects were evaluated for symptoms corresponding to various dermatological abnormalities, including, for example: erythema (e.g., redness of the skin caused by capillary congestion); scaling (e.g., flaking of the skin); fissuring (e.g., cracks in the skin that may bleed); xerosis (e.g., dry skin); edema (e.g., swelling of the skin); vesiculation (e.g., formation of blisters); and lichenification (e.g., the formation of thick, leathery skin, usually the result of constant scratching and rubbing).
- erythema e.g., redness of the skin caused by capillary congestion
- scaling e.g., flaking of the skin
- fissuring e.g., cracks in
- TEWL TEWL
- TEWL TEWL was measured in units of grams of water lost per square-centimeter per hour (g/cm 2 h).
- the mean dorsal TEWL 105 was 17.12 g/cm 2 h and the mean palmar TEWL 110 was 45.71 g/cm 2 h.
- dorsal 130 and palmar 135 values decreased again to 11.04 g/cm 2 h and 18.51 g/cm 2 h, respectively. This corresponded to a 20.00% reduction of dorsal TEWL and a 44.75% reduction of palmar TEWL from day seven (7) thru day fourteen (14).
- the aggregate effect observed over the course of the entire study corresponded to a 35.51% reduction of dorsal TEWL and a 59.51% reduction of palmar TEWL from baseline thru day fourteen (14).
- untreated sites 125, 140 were measured on medial inner-wrist patches for each subject on day seven (7) and day fourteen (14), respectively.
- the mean value for TEWL control readings on wrist patches at seven (7) days 125 corresponded to 30.00 g/cm h.
- the mean value for TEWL control readings on wrist patches at fourteen (14) days 140 was 32.5 g/cm 2 h.
- both dorsal and palmar TEWL readings were dramatically reduced.
- the mean value for TEWL control readings on wrist patches at seven (7) days 215 corresponded to 30.00 g/cm h.
- the mean value for TEWL control readings on wrist patches at fourteen (14) days 225 was 32.5 g/cm 2 h.
- the combined averages of mean dorsal and palmar TEWL readings were dramatically reduced.
- Figures 3 and 4 illustrate histopathology associated with a representative dermatological inflammatory process ⁇ i.e., contact dermatitis) both before and following application of an emollient sanitizer composition corresponding to Example 1.
- Figure 3 corresponds to baseline photomicrograph results of a 3mm punch biopsy of untreated skin stained with Hematoxylin and Eosin at a magnification of 40Ox.
- the histology depicts a thickening of the stratum corneum 310 and a mild-moderate inflammatory infiltrate of polymorphonuclear leukocytes (PMN' s; i.e., white blood cells) 320 in the basal portion of the epidermis.
- PMN' s polymorphonuclear leukocytes
- This histological evaluation is consistent with common signs and symptoms associated with hand irritant contact dermatitis (e.g., redness, dryness, and fissuring).
- Figure 4 corresponds to measurement at fourteen (14) days post-treatment following use of the emollient sanitizing formulation of Example 1.
- the photomicrograph was made from a 3mm punch biopsy stained with Hematoxylin and Eosin at 40Ox magnification.
- the vacuolization observed as open areas in the stratum corneum 310 depicted in Figures 3 and 4 correspond to artifacts of the method employed to prepare the cross-sectional samples for photomicrography and, as such, represent no difference between the photomicrographs.
- the histology of Figure 4 demonstrates a less thick stratum corneum 310 and less inflammatory (PMN) infiltrate 420 residing in the basal portion of the epidermis.
- emollient sanitizing compositions corresponding to various representative embodiments of the present invention generally provide a demonstrated reduction in transepidermal water loss, increase in substantivity and smooth skin-feel, as well as anti- inflammatory activity useful for the mitigation of adverse dermatitic symptoms.
- any method or process embodiment may be executed in any order and are not limited to the specific order presented in the claims.
- the components and/or elements recited in any apparatus or composition embodiment may be assembled or otherwise operationally configured in a variety of permutations to produce substantially the same result as the present invention and are accordingly not limited to the specific configuration recited in claims.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010501014A JP2010522757A (ja) | 2007-03-29 | 2008-03-29 | 哺乳動物外皮の皮膚炎症状の皮膚軟化殺菌製剤による処置 |
CA002678780A CA2678780A1 (fr) | 2007-03-29 | 2008-03-29 | Traitement des symptomes de dermatose touchant un tegument mammalien avec des formulations desinfectantes emollientes |
EP08742370.3A EP2124868A4 (fr) | 2007-03-29 | 2008-03-29 | Traitement des symptômes de dermatose touchant un tégument mammalien avec des formulations désinfectantes émollientes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92060407P | 2007-03-29 | 2007-03-29 | |
US60/920,604 | 2007-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008121355A1 true WO2008121355A1 (fr) | 2008-10-09 |
Family
ID=39808603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/004120 WO2008121355A1 (fr) | 2007-03-29 | 2008-03-29 | Traitement des symptômes de dermatose touchant un tégument mammalien avec des formulations désinfectantes émollientes |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2124868A4 (fr) |
JP (1) | JP2010522757A (fr) |
CA (1) | CA2678780A1 (fr) |
WO (1) | WO2008121355A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011173815A (ja) * | 2010-02-23 | 2011-09-08 | Nippon Shokuhin Kk | 皮膚消毒用組成物 |
WO2013080205A1 (fr) * | 2011-11-30 | 2013-06-06 | Ibr - Israeli Biotechnology Research Ltd. | Extrait de jojoba utilisé dans l'amélioration des fonctions barrières de la peau |
WO2012148706A3 (fr) * | 2011-04-29 | 2013-08-15 | International Flora Technologies , Ltd. | Insaponifiables en taux élevé et leurs méthodes d'utilisation |
CN105748309A (zh) * | 2016-05-04 | 2016-07-13 | 浙江焜之琳生物医药科技股份有限公司 | 一种免洗抗菌洗手液及制备方法 |
WO2017222429A1 (fr) | 2016-06-20 | 2017-12-28 | Sca Hygiene Products Ab | Composition désinfectante pour les mains |
WO2018185508A1 (fr) * | 2017-04-04 | 2018-10-11 | Gojo Industries Inc | Procédés et composés permettant d'augmenter l'efficacité virucide dans des systèmes hydroalcooliques |
CN111617063A (zh) * | 2020-05-29 | 2020-09-04 | 广州润虹医药科技股份有限公司 | 一种免洗消毒液 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60030090T2 (de) | 2000-04-06 | 2007-02-15 | Quest International B.V. | Aromatisieren von Nahrungsmitteln mit Verbindungen die ein mit zwei spezifischen Atomen oder Gruppen verbundenes Schwefelatom enthalten |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968530A (en) * | 1997-10-17 | 1999-10-19 | International Flora Technologies, Inc. | Emollient compositions |
US6544534B2 (en) * | 2001-08-21 | 2003-04-08 | Janice K. Malmgren | Conditioner that provides skin like an angel |
US6977082B2 (en) * | 2001-03-29 | 2005-12-20 | The Dial Corporation | High efficacy antibacterial compositions having enhanced esthetic and skin care properties |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2151774C (fr) * | 1994-06-27 | 1999-04-06 | Minh Quang Hoang | Formulations pour la desinfection de la peau |
US6436379B1 (en) * | 1997-10-17 | 2002-08-20 | International Flora Technologies Ltd. | Emollient for cuticle treatment and delivery system therefore |
US6022551A (en) * | 1998-01-20 | 2000-02-08 | Ethicon, Inc. | Antimicrobial composition |
JP2000319171A (ja) * | 1999-03-03 | 2000-11-21 | Nof Corp | 殺菌性皮膚外用剤組成物 |
US7435424B1 (en) * | 2000-01-03 | 2008-10-14 | International Flora Technologies, Ltd. | High unsaponifiables and methods of using the same |
US20090191243A9 (en) * | 2000-01-03 | 2009-07-30 | Hill John C | High unsaponifiables and methods of using the same and its derivatives and uses thereof |
IT1317890B1 (it) * | 2000-08-03 | 2003-07-15 | Idi Irccs | Preparato da utilizzare come componente lipidico nei cosmetici. |
TNSN02063A1 (en) * | 2001-07-07 | 2005-12-23 | Egyptian Natural Oil Co Natoil | The medical effect of jojoba oil |
-
2008
- 2008-03-29 EP EP08742370.3A patent/EP2124868A4/fr not_active Withdrawn
- 2008-03-29 JP JP2010501014A patent/JP2010522757A/ja active Pending
- 2008-03-29 CA CA002678780A patent/CA2678780A1/fr not_active Abandoned
- 2008-03-29 WO PCT/US2008/004120 patent/WO2008121355A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968530A (en) * | 1997-10-17 | 1999-10-19 | International Flora Technologies, Inc. | Emollient compositions |
US6977082B2 (en) * | 2001-03-29 | 2005-12-20 | The Dial Corporation | High efficacy antibacterial compositions having enhanced esthetic and skin care properties |
US6544534B2 (en) * | 2001-08-21 | 2003-04-08 | Janice K. Malmgren | Conditioner that provides skin like an angel |
Non-Patent Citations (1)
Title |
---|
See also references of EP2124868A4 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8529970B2 (en) | 2000-01-03 | 2013-09-10 | International Flora Technologies, Ltd. | High unsaponifiables and methods of using the same |
JP2011173815A (ja) * | 2010-02-23 | 2011-09-08 | Nippon Shokuhin Kk | 皮膚消毒用組成物 |
WO2012148706A3 (fr) * | 2011-04-29 | 2013-08-15 | International Flora Technologies , Ltd. | Insaponifiables en taux élevé et leurs méthodes d'utilisation |
US9949918B2 (en) | 2011-11-30 | 2018-04-24 | IBR—Israeli Biotechnology Research Ltd. | Jojoba extract useful in improving skin barrier functions |
WO2013080205A1 (fr) * | 2011-11-30 | 2013-06-06 | Ibr - Israeli Biotechnology Research Ltd. | Extrait de jojoba utilisé dans l'amélioration des fonctions barrières de la peau |
CN103957884A (zh) * | 2011-11-30 | 2014-07-30 | Ibr以色列生物科技研究有限公司 | 可用于改善皮肤屏障功能的荷荷巴提取物 |
CN105708870A (zh) * | 2011-11-30 | 2016-06-29 | Ibr以色列生物科技研究有限公司 | 可用于改善皮肤屏障功能的荷荷巴提取物 |
AU2012345458B2 (en) * | 2011-11-30 | 2017-07-27 | Ibr- Israeli Biotechnology Research Ltd. | Jojoba extract useful in improving skin barrier functions |
CN105748309A (zh) * | 2016-05-04 | 2016-07-13 | 浙江焜之琳生物医药科技股份有限公司 | 一种免洗抗菌洗手液及制备方法 |
WO2017222429A1 (fr) | 2016-06-20 | 2017-12-28 | Sca Hygiene Products Ab | Composition désinfectante pour les mains |
CN109414397A (zh) * | 2016-06-20 | 2019-03-01 | 易希提卫生与保健公司 | 手部消毒组合物 |
AU2016410550B2 (en) * | 2016-06-20 | 2019-06-06 | Essity Hygiene And Health Aktiebolag | Hand sanitizing composition |
RU2714885C1 (ru) * | 2016-06-20 | 2020-02-20 | Эссити Хайджин Энд Хелт Актиеболаг | Дезинфицирующая композиция для рук |
EP3471696A4 (fr) * | 2016-06-20 | 2020-03-11 | Essity Hygiene And Health Aktiebolag | Composition désinfectante pour les mains |
WO2018185508A1 (fr) * | 2017-04-04 | 2018-10-11 | Gojo Industries Inc | Procédés et composés permettant d'augmenter l'efficacité virucide dans des systèmes hydroalcooliques |
CN111617063A (zh) * | 2020-05-29 | 2020-09-04 | 广州润虹医药科技股份有限公司 | 一种免洗消毒液 |
Also Published As
Publication number | Publication date |
---|---|
EP2124868A4 (fr) | 2014-06-11 |
CA2678780A1 (fr) | 2008-10-09 |
EP2124868A1 (fr) | 2009-12-02 |
JP2010522757A (ja) | 2010-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080254150A1 (en) | Management of dermatitic symptoms of mammalian integument with emollient disinfectant formulations | |
Draelos | The science behind skin care: Cleansers | |
US6342208B1 (en) | Oil-in-water emulsion containing C10-C24 fatty acid derivatives for treating skin of mammals | |
Levin et al. | A guide to the ingredients and potential benefits of over-the-counter cleansers and moisturizers for rosacea patients | |
WO2008121355A1 (fr) | Traitement des symptômes de dermatose touchant un tégument mammalien avec des formulations désinfectantes émollientes | |
EP2953603A1 (fr) | Composition liquide de traitement de la peau et des cheveux exempte de sel non ionique | |
CN107998028A (zh) | 一种沐浴露及其制备方法 | |
CN107982135A (zh) | 一种洗发水及其制备方法 | |
CN108024914A (zh) | 改善皮肤的水合作用或润湿作用的方法 | |
JP5765744B2 (ja) | アトピー性皮膚炎の予防剤または治療剤、および外用剤 | |
CN1357321A (zh) | 减少炎症和红斑的方法 | |
WO2007132273A2 (fr) | Agents thérapeutiques | |
EP2549976B1 (fr) | Association de principes actifs respectueuse de la peau pour lutter contre l'acné | |
JP3479048B2 (ja) | 化粧料及び不織布含浸化粧料 | |
DE19643587A1 (de) | Antiadhäsive Sterole und Sterolderivate | |
WO2001078659A1 (fr) | Lotions laiteuses, preparations cosmetiques, agents de nettoyage de la peau et articles de nettoyage de la peau | |
DE19643586A1 (de) | Gegen Mikroorganismen, Viren, Parasiten und Protozoen wirksame Sterole und Sterolderivate | |
RU2816954C2 (ru) | Средство для интимной гигиены | |
Panigrahi et al. | Cosmeceutical Cleansers | |
CN102727397A (zh) | 乳状清洁组合物 | |
BE1025392B1 (nl) | Octenidinehydrochloride bevattende emulsies | |
Devre et al. | FORMULATION AND EVALUATION OF ANTIBACTERIAL POLYHERBAL SOAP | |
Khalid | Cold Creams Uncovered: A Critical Analysis of Ingredients and Benefits | |
WO2025003996A1 (fr) | Méthode d'utilisation d'une composition de soin de la peau | |
CN118680842A (zh) | 一种温和清洁组合物及含有该组合物的起泡型沐浴油 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08742370 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2678780 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008742370 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010501014 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |